Amylin ( AMLN) and Onyx ( ONXX ) gained 14.8% and 10%, respectively. In clinical and regulatory news, Genmab and GlaxoSmithKline ( GSK ) reported positive preliminary results from a late-stage trial on ofatumumab for patients with chronic lymphocytic leukaemia, or CLL, and said they plan to file for U.S. and European regulatory approval by the end of the year. If approved, the drug could compete with Genentech ( DNA) and Biogen Idec's ( BIIB ) Rituxan. Glaxo shares ended essentially flat, while Biogen Idec fell $1.51, or 2%, to $69.76 and Genentech edged up 25 cents, or 0.3%, to $95.25. A legal and regulatory item, generic-drug maker Barr Pharmaceuticals ( BRL) is striking again. The company said it is challenging a patent held by Belgian drug maker UCB Inc. for 5-mg tablets of hay fever treatment Xyzal. UCB filed a patent infringement lawsuit against Barr on Wednesday. The drug was developed by Sepracor ( SEPR) and licensed to UCB.